Received Apr 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 3 | B0005 | IM / RA |
| FLU3 | INFLUENZA (SEASONAL) (FLUCELVAX) | SEQIRUS, INC. | UNK | 391417 | IM / LA |
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 4T93R | IM / LA |
No adverse event reported. Reporting per Moderna after a temperature excursion, vaccine remained viable after the excursion per Moderna.
insomnia, seasonal allergies, acute kidney injury, acute on chronic combined systolic and diastolic congestive heart failure
hypertensive heart and chronic kidney disease with heart failure and stage 1-4 chronic kidney disease, NSTEMI, essential hypertension, acute on chronic congestive heart failure, aneurysm of ascending aorta without rupture, dilated cardiomyopathy, nonrheumatic aortic valve insufficiency, pulmonary hypertension, closed fracture of left clavicle, dizziness, neck pain, subclinical hypothyroidism, sensorineural hearing loss of left ear, conductive hearing loss left ear, tinnitus bilateral, gastrointestinal hemorrhage, chronic gastric ulcer, stage 3b chronic kidney disease, methamphetamine abuse, tobacco use, bipolar 1 disorder, hemoglobin e-beta thalassemia, iron deficiency, history of gastric bypass, gun shot wound, hyperlipidemia, other hemoglobinopathies, anemia of chronic disease, microcytosis,
dapagliflozin propanediol, metoprolol succinate, furosemide, pantoprazole, cetirizine, sacubitril valsartan,
aspirin, ciprofloxacin, nsaids, sulfonamide antibiotics
N/A